. Its upregulation by chronic hypoxia is associated with enhanced myogenic tone, and genetic deletion of trpv4 suppresses the development of chronic hypoxic pulmonary hypertension (CHPH). Here we further examine the roles of TRPV4 in agonist-induced pulmonary vasoconstriction and in the enhanced vasoreactivity in CHPH. Initial evaluation of TRPV4-selective antagonists HC-067047 and RN-1734 in KCl-contracted pulmonary arteries (PAs) of trpv4 Ϫ/Ϫ mice found that submicromolar HC-067047 was devoid of off-target effect on pulmonary vasoconstriction. Inhibition of TRPV4 with 0.5 M HC-067047 significantly reduced the sensitivity of serotonin (5-HT)-induced contraction in wild-type (WT) PAs but had no effect on endothelin-1 or phenylephrine-activated response. Similar shift in the concentrationresponse curve of 5-HT was observed in trpv4 Ϫ/Ϫ PAs, confirming specific TRPV4 contribution to 5-HT-induced vasoconstriction. 5-HT-induced Ca 2ϩ response was attenuated by HC-067047 in WT PASMCs but not in trpv4 Ϫ/Ϫ PASMCs, suggesting TRPV4 is a major Ca 2ϩ pathway for 5-HT-induced Ca 2ϩ mobilization. Nifedipine also attenuated 5-HT-induced Ca 2ϩ response in WT PASMCs but did not cause further reduction in the presence of HC-067047, suggesting interdependence of TRPV4 and voltage-gated Ca 2ϩ channels in the 5-HT response. Chronic exposure (3-4 wk) of WT mice to 10% O 2 caused significant increase in 5-HT-induced maximal contraction, which was partially reversed by HC-067047. In concordance, the enhancement of 5-HT-induced contraction was significantly reduced in PAs of CH trpv4 Ϫ/Ϫ mice and HC-067047 had no further effect on the 5-HT induced response. These results suggest unequivocally that TRPV4 contributes to 5-HT-dependent pharmaco-mechanical coupling and plays a major role in the enhanced pulmonary vasoreactivity to 5-HT in CHPH.
TRPV4; serotonin; pulmonary arteries; chronic hypoxia; pulmonary hypertension TRANSIENT RECEPTOR POTENTIAL vanilloid 4 (TRPV4), a member of the transient receptor potential (TRP) channel superfamily, is a Ca 2ϩ and Mg 2ϩ permeating nonselective cation channel widely distributed in various tissues including kidney, brain, lung, aorta, heart, liver, and skeletal muscle (32) . TRPV4 is a highly versatile channel. It can be activated by a variety of physical and chemical stimuli, including abnormal osmolarity (37, 48) , sheer stress (24, 30) , pressure (59, 60) , heat (5, 36, 68) , endogenous substances such as arachidonic acid and its cytochrome P450-derived metabolites [epoxyeicosatrienoic acids (EETs); 64, 65, 67] , as well as synthetic compounds such as PKC-activating and nonactivating phorbol ester derivatives (66) . It is involved in a wide range of physiological functions, including osmotic and volume regulation, thermo-sensing and regulation, mechanosensation in endothelium and urinary bladder, vascular and epithelium permeability, synaptic transmission, nociception, as well as bone formation and remodeling (16) .
TRPV4 channels are highly expressed in endothelial and vascular smooth muscle cells of systemic and pulmonary vasculatures (10, 11, 30, 64, 66, 73) . Accumulating evidence suggests that TRPV4 plays important roles in the regulation of vascular functions. In systemic arteries, endothelial TRPV4 is critically involved in shear stress or acetylcholine-induced vasodilation (24, 30, 75) . Activation of endothelial TRPV4 generates Ca 2ϩ signals to mediate Ca 2ϩ -dependent release of nitric oxide and endothelium-derived hyperpolarizing factors (EDHFs), as well as to activate endothelial small and intermediate-conductance Ca 2ϩ -activated K ϩ channels to promote vasodilation (31, 56) . Stimulation of TRPV4 channels in arterial smooth muscle cells by the putative EDHF, 11,12-EET, can also promote vasodilation by increasing local Ca 2ϩ release from ryanodine receptor-gated Ca 2ϩ stores, which in turn activates large-conductance Ca 2ϩ -activated K ϩ channels to cause membrane hyperpolarization (9 -11) .
In the lungs, TRPV4 is a critical regulator of endothelial barrier integrity. Mechanical activation of endothelial TRPV4 by high vascular pressure or high-peak inflation pressure ventilation causes acute increase in pulmonary vascular permeability, disruption of alveolar-septal barrier, and pulmonary edema, which are mimicked by pharmacological activation of TRPV4, resolved by TRPV4 antagonists and prevented in trpv4-deleted mice (2, 23, 27, 61, 74) . In rat pulmonary arterial smooth muscle, TRPV4 is the most abundantly expressed TRPV channel subtype. It can be activated by the PKCnonactivating phorbol ester derivative 4␣-phorbol-12,13-didecanoate (4␣-PDD) and hypotonic solution-induced mechanical stress (72, 73) . Our recent study showed that TRPV4 in rat pulmonary arteries (PAs) is the only channel upregulated by chronic hypoxia among all 14 TRPV and TRPM channel subtypes (72) . Its upregulation is associated with enhanced TRPV4-dependent Ca 2ϩ influx, elevation of resting [Ca 2ϩ ] i in pulmonary arterial smooth muscle cells (PASMCs), and the appearance of an intravascular pressure-activated myogenic tone. Moreover, the development of chronic hypoxic pulmonary hypertension (CHPH) and vascular remodeling is delayed and suppressed in trpv4 Ϫ/Ϫ mice. These findings suggest that TRPV4 is an important contributing player in the pathogenesis of CHPH.
Besides these observations, our knowledge on the physiological functions of TRPV4 in PASMCs is very limited. For example, the contribution of TRPV4 in agonist-induced contraction and its role in the enhanced pulmonary vascular reactivity in pulmonary hypertension have not been examined. Previous studies show that serotonin (5-HT) activates an arachidonic acid-dependent nonselective cation current, which has pharmacological properties similar to TRPV4 in PASMCs (8, 22) . In heterologous expression systems and endothelial cells, TRPV4 coassembles with TRPC1 forming heteromeric channels to mediate store-operated Ca 2ϩ entry (SOCE) and flowinduced Ca 2ϩ entry (42) (43) (44) . The TRPV4 channel also participates in receptor-operated Ca 2ϩ entry (ROCE) in ciliated airway epithelial cells (40) . In PAs, most agonists induce vasoconstriction through phospholipase C (PLC)-mediated hydrolysis of phosphatidylinositol-4,5-bisphosphate (PIP 2 ) to form inositol 1,4,5-trisphosphate (InsP 3 ), which releases Ca 2ϩ from sarcoplasmic reticulum and activates SOCE, and diacylglycerol, which activates protein kinase C and ROCE. Many agonists also stimulate phospholipase A 2 (PLA 2 ) to mediate release of arachidonic acid and its metabolites (26, 33, 34, 62) . Hence, we hypothesize that TRPV4 of PASMCs may contribute to agonist-induced vasoconstriction and participate in the regulation of pulmonary vascular reactivity in pulmonary hypertension. In the present study, we aimed to test this hypothesis by using the currently available TRPV4-selective antagonists and trpv4 Ϫ/Ϫ mice to probe the contribution of TRPV4 in agonist-induced contraction in PAs of normal and CHPH mice.
1

MATERIALS AND METHODS
Chronic hypoxia exposure. Adult male trpv4
Ϫ/Ϫ mice and agematched wild-type (WT) mice (C57BL/6J; 8 wk old) were placed in a hypoxic chamber (10% O 2) for 3-4 wk to develop hypoxic pulmonary hypertension as described and characterized previously (38) . The chamber was constantly flushed with hypoxic air to maintain normal CO 2 concentration. Cages were cleaned and replenished with food and water once a week. Normoxic mice were housed in room air as controls.
Measurement of hemodynamic parameters and right heart hypertrophy. Animals were anesthetized with an intraperitoneal injection of pentobarbital sodium (50 mg/kg). Pulmonary hypertension was evaluated by measuring right ventricular systolic pressure (RVSP), mean pulmonary arterial pressure (mean PAP), pulmonary vascular resistance (PVR), and right ventricular hypertrophy. The mice were ventilated by a volume-controlled ventilator (0.018 ml/g body wt and 130 cycles/min, Inspira ASV; Harvard Apparatus, Holliston, MA). RVSP and PAP were monitored using a Mikro-Tip pressure catheter (SPR-1000; Millar Instruments, Houston, TX) via direct puncture of the right ventricle and advanced into the main PA via an open-chest approach. A four-electrode pressure-volume catheter (PVR-1030; Millar Instruments) was placed through the left ventricular apex to record chamber volume by impedance. Simultaneous beat-to-beat measurement of aortic blood flow was determined by placing a transonic flow-probe (MA1PRB; Transonics Tech, Ithaca, NY) at the ascending aorta to provide the conversion factor between flow probe and P-V catheter for accurate calibration of each individual animal at the end of each experiment. Pulmonary vascular resistance (PVR) was calculated by the equation of (mean PAP Ϫ Pleft atrium)/cardiac output, assuming that the diastolic pressure of the left atrium is zero. Heart and lung were then harvested after exsanguination for vascular reactivity experiments. RV was separated from the left ventricle and septum (LV ϩ S) and then blotted dry to weigh immediately. The mass ratio of RV/(LV ϩ S) was determined. All animal procedures were performed with approval by the Johns Hopkins Animal Care and Use Committee.
Isometric tension measurement of intralobar PAs. Intralobar PAs (100 -300 m OD) were isolated, freed of connective tissue, and cut into 1.8-mm segments in oxygenated modified Krebs solution containing (in mM) 118 NaCl, 4.7 KCl, 0.57 MgSO4, 1.18 KH2PO4, 25 NaHCO 3, 10 dextrose, and 1.25 CaCl2. Endothelium was either kept intact or disrupted by gentle rubbing of the lumen with a moose hair; arterial rings were then mounted on a wire myograph chamber (model 6200; Danish Myo Technology, Aahrus, Denmark), which was filled with 16% O2 plus 5% CO2 gassed modified Krebs solution, using two stainless steel wires, and isometric force development was recorded (PowerLab; ADInstruments, Colorado Springs, CO). The resting tension was calculated by the normalization module of Labchart7 with the targeting pressure setting at 15 mmHg or 25 mmHg for normoxic animals and hypoxic ones, respectively. After 60 min equilibration, PA rings were exposed to 60 mM KCl three times to establish viability and maximum contraction and to phenylephrine (PE, 1 M) followed by ACh (10 M) to verify the intactness or complete disruption of endothelium. The active tension induced by the agonist was normalized to maximum tension generated by 60 mM of KCl.
Isolation and transient culture of PASMCs. Intralobar PAs from WT and trpv4 Ϫ/Ϫ mice were isolated and the endothelium was removed. Endothelium-denuded PAs were allowed to recover for 30 min in cold (4°C) HBSS, followed by 20 min in reduced-Ca 2ϩ (20 M) HBSS at room temperature. The tissue was digested at 37°C for 15 min in 20 M Ca 2ϩ HBSS containing collagenase (type I; 1,750 U/ml), papain (9.5 U/ml), BSA (2 mg/ml), and dithiothreitol (1 mM) and then washed with Ca 2ϩ -free HBSS to stop digestion. PASMCs were dispersed gently by trituration with a small-bore pipette in Ca 2ϩ -free HBSS at room temperature. Cells were then placed on 25-mm glass coverslips. PASMCs were cultured transiently (12 h) in Ham's F-12 medium (with L-glutamine) supplemented with 0.5% FCS (Mediatech, Herndon, VA), 100 U/ml streptomycin, and 0.1 mg/ml penicillin. Culture medium was then changed to SmGM (Lonza, Walkersville, MA) supplemented with growth factor and 10% FCS. PASMCs were allowed to grow for 3-4 more days and were then serum starved for 12 h before experiments.
Measurement of intracellular [Ca 2ϩ ]i. [Ca 2ϩ ]i was monitored using the membrane-permeable Ca 2ϩ -sensitive fluorescent dye fluo 3-AM. PASMCs were loaded with 5-10 M fluo 3-AM (dissolved in DMSO with 20% pluronic acid) for 45 min at room temperature (ϳ23°C) in normal Tyrode solution containing the following (in mM): 137 NaCl, 5.4 KCl, 2 CaCl2, 1 MgCl2, 10 HEPES, and 10 glucose, pH 7.4 (adjusted with NaOH). Cells were then washed and rested for 15-30 min to allow for complete deesterification of cytosolic dye. Fluo-3 was excited at 488 nm, and emission light at Ͼ515 nm was detected using a Nikon Diaphot microscope equipped with a microfluorometer. Protocols were executed and data were collected online with a Digidata analog-to-digital interface and a pClamp software package (Axon Instruments, Foster City, CA). [Ca 2ϩ ]i was calibrated using a pseudoratio method (4) with the following equation: Chemicals and drugs. RN-1734 was purchased from Calbiochem (Billerica, MA) and HC-067047, 5-HT, collagenase, protease, papain, serum albumin, dithiothreitol, antibiotics, and other chemicals were purchased from Sigma Chemical (St. Louis, MO). Ham's F-12 medium was purchased from Mediatech (Herndon, VA), and SmGM and growth factors were purchased from Lonza. Fluo 3-AM and pluronic acid were purchased from Molecular Probes (Eugene, OR). Stock solutions of HC-067047 and RN-1734 were prepared in DMSO and diluted 1:1,000 in 2 mM Ca 2ϩ -Tyrode solution before use.
RESULTS
Evaluation of TRPV4 antagonists for the study of pulmonary vascular reactivity.
To evaluate the contribution of TRPV4 in agonist-induced vasoreactivity, we first examined the effect of the TRPV4 antagonist HC-067047 on PE-induced isometric contraction of endothelium-denuded (ECϪ) PAs of WT mice. Application of 1 nM to 10 M PE activated concentrationdependent contraction of PAs with a maximal response (E max ) of 96.7 Ϯ 2.37% and a pD 2 (defined as Ϫlog EC 50 ) of 7.7 Ϯ 0.1 (n ϭ 6; Fig. 1A ). Preincubation of PA rings with 5 M HC-067047, a concentration used previously on PASMCs (6, 47) , for 15 min caused significant reduction in the maximal response (E max ϭ 63.0 Ϯ 7.6, n ϭ 10, P Ͻ 0.01) and the pD 2 (7.2 Ϯ 0.08, P Ͻ 0.01) of PE ( Fig. 1, A-C) . To validate that the vasorelaxant effect of HC-067047 was specifically due to TRPV4 inhibition, the experiments were repeated in PAs of trpv4 Ϫ/Ϫ mice. However, the concentration-response curve of PE generated in PAs of trpv4 Ϫ/Ϫ mice was identical to that of WT (E max ϭ96.5 Ϯ 2.3, pD 2 ϭ 7.8 Ϯ 0.06, n ϭ 8; Fig. 1 ,
A-C). Preincubation of trpv4
Ϫ/Ϫ PAs with 5 M HC-067047 caused significant suppression of PE-induced contraction (E max ϭ 57.9 Ϯ 8.9 and pD 2 ϭ 7.3 Ϯ 0.06, n ϭ 4) similar to that observed in WT PAs (Fig. 1, D-F) . Moreover, pretreatment of trpv4 Ϫ/Ϫ PAs with another TRPV4 antagonist, RN-1734 (30 M), also significantly inhibited the PE-induced contraction (E max ϭ 74.9 Ϯ 5.3 and pD 2 ϭ 7.2 Ϯ 0.1, n ϭ 4). These results indicate that both HC-047067 and RN-1734 at the commonly used concentrations could suppress PE-induced PA contraction through mechanisms other than TRPV4 inhibition. To determine the optimal concentration of HC-047067 and RN-1734 with minimal off-target effects, we tested the vasorelaxant effect of the two antagonists at various concentrations on K ϩ (60 mM)-induced contraction in PAs of trpv4
PE (M)
mice. HC-047067 at 1 and 5 M caused concentration-dependent relaxation of both endothelium-intact (ECϩ) and ECϪ PAs, while 0.5 M HC-047067 had no significant effect on K ϩ -induced PA contraction (Fig. 2, A and B) . RN-1734 at concentrations of 5, 10, and 30 M caused significant relaxation of K ϩ -precontracted PAs of trpv4 Ϫ/Ϫ mice (Fig. 2, C and  D) . Since the IC 50 of HC-047067 and RN-1734 for TRPV4 inhibition is 17 nM and 5.9 M, respectively (17, 63) , the significant TRPV4-independent effects of RN-1734 at 5 M precluded its use for the experiments on pulmonary vascular reactivity. In contrast, HC-067047 at 0.5 M has minimal off-target effects on voltage-gated Ca 2ϩ channels (VDCC) and the downstream mechanisms for PA contraction; hence this concentration of HC-067047 was used in all other experiments through the study.
Contributions of TRPV4 in pulmonary vasoreactivity to 5-HT. To evaluate the contribution of the TRPV4 channel in agonist-induced pulmonary vascular reactivity, we examined the effects of HC-067047 and trpv4 gene knockout on the contractile effects of PE, endothelin-1 (ET-1), and 5-HT in isolated PAs with and without endothelium. Concentrationresponse curves of PE, ET-1, and 5-HT generated in ECϩ PAs of WT mice generally had significantly lower E max and pD 2 values compared with those in ECϪ PAs, consistent with a vasodilatory influence from endothelium ( Figs. 3 and 4) . Inhibition of TRPV4 with 0.5 M HC-067047, however, had no noticeable effect on the E max and pD 2 of PE or ET-1-induced contraction in both ECϩ and ECϪ PAs (Fig. 3) . In addition, concentration-response relations of PE and ET-1 obtained from PAs of trpv4 Ϫ/Ϫ mice were similar to those of WT control. These results suggest that TRPV4 is not involved in PE and ET-1-mediated pulmonary vasoconstriction. In contrast, HC-067047 caused a significant reduction in pD 2 of 5-HT (control: 7.8 Ϯ 0.06, n ϭ 5; HC-067047: 7.5 Ϯ 0.09, n ϭ 5, P Ͻ 0.05), without affecting the maximal response in ECϪ PAs of WT mice (Fig. 4, A-C) . The contribution of TRPV4 to the sensitivity of 5-HT-induced contraction was confirmed in endothelium-denuded PAs of trpv4 Ϫ/Ϫ mice, where the concentrationresponse curve was shifted significantly to the right and overlapped with the relation generated in WT PAs in the presence of HC-067047. There was no significant difference in the 5-HT-induced contraction in ECϩ WT PAs after HC-067047 treatment or in trpv4 Ϫ/Ϫ PAs, suggesting that endothelial TRPV4 inhibition counteracts the influence due to inhibition of TRPV4 of PASMCs. These results suggest that TRPV4 in PASMCs participates in the 5-HT-activated pharmaco-mechanical coupling for PA contraction.
Contributions of TRPV4 to 5-HT-induced Ca 2ϩ response in PASMCs.
To further examine whether 5-HT mobilizes intracellular Ca 2ϩ via TRPV4 channels, the specificity of HC-067047 on Ca 2ϩ response activated by 5-HT was evaluated in PASMCs of trpv4 Ϫ/Ϫ mice. 5-HT (1 M) elicited Ca 2ϩ response with a transient peak followed by a sustained Ca 2ϩ increase (Fig. 5, A and B) . The response was unaltered in PASMCs after preincubation with 0. side effect on Ca 2ϩ influx or release. In contrast, HC-067047 caused significant inhibition of both the peak (control: 657.8 Ϯ 96.4 nM, n ϭ 14; HC-067047: 220.9 Ϯ 39.7 nM, n ϭ 17, P Ͻ 0.001) and the sustained Ca 2ϩ response (control: 171.8 Ϯ 35.1 nM, n ϭ 14; HC-067047: 43.6 Ϯ 15.2 nM, n ϭ 17, P Ͻ 0.001) activated by 5-HT in PASMCs of WT mice (Fig. 5, C and D) . The reduction in the peak response was comparable to, while the inhibition of the sustained response was stronger than, that caused by the voltage-dependent Ca 2ϩ channel blocker nifedipine (1 M), which is known to inhibit 5-HT-induced contraction of PAs (20, 58 3 receptors with xestospongin C (3 M) caused only a small reduction in the peak response without altering the sustained Ca 2ϩ increase (Fig. 5, E and F) . These results are in line with the myograph data suggesting that 5-HT activates Ca 2ϩ influx via TRPV4 channels to participate in the 5-HT-mediated pulmonary vasoconstriction. It has to be cautioned, however, that the Ca 2ϩ response and relative contribution of Ca 2ϩ influx and release in isolated PASMCs could be quantitatively different from those in isolated PAs.
Chronic hypoxia-induced pulmonary hypertension in WT and trpv4
Ϫ/Ϫ mice. It is well documented that pulmonary vasoreactivity to many vasoactive agonists, including 5-HT, is enhanced in CHPH (39, 45, 46, 58) . Therefore, we further evaluated the contribution of TRPV4 in 5-HT-induced contraction in CH WT and trpv4 Ϫ/Ϫ mice. To verify the successful generation of a CHPH model, hemodynamic parameters of normoxic and CH mice were measured using an open-chest approach and right heart hypertrophy was determined. Consistent with our previous observation (72), deletion of the TRPV4 gene had little effect on RVSP and RV/(LV ϩ S) ratio in normoxic mice, but significantly diminished the CH-induced increase in RVSP and right heart hypertrophy (Fig. 6, C-E) . After 3-4 wk of hypoxia exposure, systolic, diastolic, and mean PAP were all elevated in WT mice (Fig. 6, F-H) . Mean PAP was increased from 11.5 Ϯ 0.18 mmHg (n ϭ 6) to 19.8 Ϯ 0.62 mmHg (n ϭ 10, P Ͻ 0.001). In contrast, trpv4 Ϫ/Ϫ mice were relatively resistant to CH, showing ablated systolic, diastolic, and mean PAP. Mean PAP of CH trpv4 Ϫ/Ϫ mice was 16.8 Ϯ 0.45 mmHg (n ϭ 10) compared with 12.5 Ϯ 0.27 mmHg (n ϭ 5, P Ͻ 0.001) in normoxic animals. Likewise, CH caused a robust elevation of PVR in CH WT mice, which was markedly suppressed in trpv4 Ϫ/Ϫ mice (CH WT: 3.25 Ϯ 0.22 vs. CH trpv4 Ϫ/Ϫ : 2.47 Ϯ 0.23 mmHg, n ϭ 8, P Ͻ 0.05) (Fig.  6I) . Cardiac output was similar in WT and trpv4 Ϫ/Ϫ mice with and without CH exposure (Fig. 6J) . These hemodynamic data further substantiate our previous finding that the TRPV4 gene contributes critically to the development of CHPH (72) .
Contribution of TRPV4 in altered pulmonary vasoreactivity in CH mice. To compare the contribution of TRPV4 in the enhanced vascular reactivity in PAs of CH mice, 5-HT-induced contraction was normalized with the developed tension activated by 60 mM KCl. K ϩ -induced PA contractions were similar among PAs of normoxic and CH WT and trpv4 Ϫ/Ϫ mice, except for a small reduction (ϳ20 -30%) in the developed tension in the endothelium-denuded PAs, presumably due to minor mechanical injury of PAs during endothelium denudation. 5-HT-induced maximal contraction was enhanced in both endothelium intact (normoxia: 101.8 Ϯ 1.09%, n ϭ 6; CH: 136.6 Ϯ 6.4%, n ϭ 7, P Ͻ 0.001) and denuded PAs (normoxia: 114.3 Ϯ 2.0%, n ϭ 5; CH: 168.6 Ϯ 8.4%, n ϭ 13, P Ͻ 0.01) of CH WT mice (Fig. 7, A and C) . The enhancement of 5-HT response was apparently greater in ECϪ PAs. HC-067047 caused a small but significant suppression of the concentration-response relation in ECϩ PAs (n ϭ 6, P Ͻ 0.05), and the inhibition was more pronounced in ECϪ PAs (n ϭ 6, P Ͻ 0.05). 5-HT-induced contraction was also significantly potentiated in both ECϩ PAs (normoxia: 104.6 Ϯ 1.2%, n ϭ 8; CH: 121.9 Ϯ 2.6%, n ϭ 16, P Ͻ 0.01) and ECϪ PAs (normoxia: 113.3 Ϯ 1.8%, n ϭ 8; CH: 147.8 Ϯ 3.8%, n ϭ 16, P Ͻ 0.001) of CH trpv4 Ϫ/Ϫ mice. The enhancement of 5-HT maximal response in CH trpv4 Ϫ/Ϫ PAs, however, was significantly less compared with those of WT, when it is evaluated as % increase in maximal response (ECϩ: WT ϭ 34.8 Ϯ 6.4%, trpv4 Ϫ/Ϫ ϭ 17.4 Ϯ 2.7% P Ͻ 0.05; ECϪ: WT ϭ 54.3 Ϯ 3.8%, trpv4 Ϫ/Ϫ ϭ 34.4 Ϯ 3.8, P Ͻ 0.05) (Fig. 7E ). HC-067047 had no further effect on the maximal response or pD 2 ( Fig. 7F) . These results clearly suggest that TRPV4 in PASMCs contributes to the enhanced 5-HT-induced maximal contraction in CH PAs.
DISCUSSION
The present study exploited both TRPV4-specific antagonists and trpv4 knockout mice to probe the contributions of TRPV4 in pulmonary vasoreactivity under normal conditions and in CHPH. The major findings are as follows: 1) inhibition of TRPV4 with a low concentration of HC-067047 or deletion of trpv4 gene caused a reduction in the sensitivity of 5-HTinduced PA contraction but had no effect on ET-1 or PEactivated pulmonary vasoconstriction; 2) Ca 2ϩ response elicited by 5-HT was significantly attenuated by HC-067047 in WT PASMCs but was not altered by the antagonist in trpv4 Ϫ/Ϫ PASMCs; 3) 5-HT-induced maximal contraction was augmented in PAs of CH WT mice and the enhanced response was partially reversed by TRPV4 inhibition; and 4) CHinduced pulmonary hypertension was significantly attenuated in trpv4 Ϫ/Ϫ mice, and the enhancement in 5-HT induced contraction was reduced in trpv4 Ϫ/Ϫ PAs. These results suggest that TRPV4 is associated specifically with 5-HT-dependent pharmaco-mechanical coupling in murine PAs and plays a significant role in the altered vasoreactivity in CHPH. In addition, our evaluation of TRPV4 antagonists in PAs of trpv4 Ϫ/Ϫ mice raises concern for the use of high concentrations of TRPV4 antagonists, especially RN-1734, in the studies of vascular functions due to their nonspecific off-target effects.
TRPV4 is a multimodal channel sensitive to diverse stimuli including osmotic cell swelling, mechanical stress, heat, endogenous ligands, and chemical stimulants, serving a wide spectrum of physiological functions in different cell types (16) . But its role in agonist-induced vasoreactivity has only been sparingly studied. There is ample evidence in other cell sys- tems suggesting that TRPV4 can be regulated by receptormediated signaling pathways. Studies on osmo-mechanosensitivity of TRPV4 show that its activity is dependent on phospholipase A 2 (PLA 2 ) activation and subsequent generation of arachidonic acid metabolites epoxyeicosatrienoic acids (5=,6=-EET, 8=,9=-EET) by cytochrome P450 epoxygenase (64, 65, 67) and/or is related to Src family tyrosine kinase-mediated tyrosine phosphorylation (69, 71) . Protein kinase C (PKC) and protein kinase A (PKA)-dependent phosphorylation can sensitize osmotic activation of TRPV4 in HEK293 cells, and the sensitization is mimicked by bradykinin, which activates PKC via a G protein-coupled mechanism (18) . Multiple PKC-dependent phosphorylation sites involved in TRPV4 sensitization have been identified (18, 51) . A recent study suggests that acetylcholine stimulates TRPV4-dependent Ca 2ϩ influx in endothelial cells through activation of PKC␣ (1). Besides PKC, InsP 3 can sensitize TRPV4 to the stimulation of 5=,6=-EET in ciliated epithelial cells, presumably through binding of the InsP 3 receptor to a TRPV4 COOH-terminal domain (19, 21) . Moreover, TRPV4 forms heteromeric channels with TRPC1 in endothelial cells and contributes to store-operated Ca 2ϩ entry (42-44), which is a major Ca 2ϩ influx pathway activated by InsP 3 -induced Ca 2ϩ release. Based on these findings in other cell systems, it seems justified to postulate that agonist receptors coupled to PLA 2 , phospholipase C (PLC), and/or tyrosine kinase are capable of stimulating TRPV4 channels in vascular smooth muscle cells.
Our experiments using three different vasoactive agonists, 5-HT, PE, and ET-1, clearly show that TRPV4 contributes specifically to the 5-HT-induced pulmonary vasoreactivity but it is not involved in PE or ET-1-mediated contractile response. In nonhypoxic mice, the contribution of TRPV4 to 5-HTinduced pulmonary vasoconstriction is evident by the rightward shift in the concentration-response relation after TRPV4 inhibition by HC-067047 and by a similar shift observed in PAs of trpv4 Ϫ/Ϫ mice. It is further supported by the marked inhibition of 5-HT-induced Ca 2ϩ response by HC-067047 in WT PASMCs, and the absence of the inhibitory effect of the antagonist in trpv4 Ϫ/Ϫ PASMCs. The specific involvement of TRPV4 in 5-HT-mediated response suggests unique coupling of the TRPV4 channel to the 5-HT-dependent signaling pathways. Previous studies showed that the 5-HT receptors 5-HT 2A , 5-HT 1B , and 5-HT 2B are expressed in PAs of rats and mice (28, 35, 46) . 5-HT-induced pulmonary vasoconstriction is mediated mainly by 5-HT 2A and to a lesser extent by 5-HT 1B in normoxic PAs (28, 46, 54) . Since 5-HT 2A stimulates PLC through G q/11 and activates PLA 2 through a PLC-independent signaling cascade (33, 34, 53) , its activation may act as a dual stimulus for TRPV4 activation through the synergistic actions of PLC-dependent activation of PKC and InsP 3 release, and PLA 2 -dependent production of the arachidonic acid metabolites EETs. Our results, therefore, provide the evidence for substantiating the claim that 5-HT indeed stimulates TRPV4 channels (8, 22) , which represents an important component of Ca 2ϩ mobilization that contributes to 5-HT-induced pulmonary vasoconstriction.
PE and ET-1 bind to ␣ 1 -adrenergic receptors and ET A receptors, respectively, both of which activate PLC through G q . ET-1 and PE have been reported to stimulate arachidonic acid release in vascular and nonvascular smooth muscles (7, 26, 62, 70) , but the participation of PLA 2 activation in ET-1 or PE-mediated pulmonary vascular reactivity is unclear (57) . It is now recognized that G protein-coupled receptors are spatially organized with members of their signaling pathways and ion channels as signalsomes or channelsomes in specialized membrane domains for efficacious signal transduction (41, 49) . The selective activation of TRPV4 by 5-HT but not by ET-1 and PE despite their similar signaling mechanisms suggests that TRPV4 is perhaps associated discriminatorily with 5-HTspecific signalsomes in PASMCs.
It is well established that 5-HT plays a major role in the development of pulmonary hypertension, which is associated with increase in plasma 5-HT levels, upregulation of 5-HT 1B and 5-HT 2B receptors (28, 35, 55) and 5-HT transporter (12) (13) (14) , as well as enhanced 5-HT-induced pulmonary vasoconstriction and PASMC proliferation (12, 15, 28, 45, 46) . Consistent with observations in the CH rat model (45, 46, 58) , we found a potentiation in the 5-HT-induced maximal contraction in PAs of CH WT-mice. The partial reversal of the enhanced 5-HT-induced contraction by HC-067047 in WT PAs and the significant reduction of the maximal response in trpv4 Ϫ/Ϫ PAs further suggest that TRPV4 contributes to the enhanced vasoreactivity developed in CHPH. It is interesting to note that the contribution of TRPV4 is apparent in the maximal response in CH PAs, instead of the sensitivity to 5-HT as observed in normoxic PAs. This could be related to alterations in 5-HT receptor subtypes in CH PAs, where 5-HT 1B and 5-HT 2B receptors expression are upregulated and the contribution of 5-HT 1B to pulmonary vasoconstriction is augmented (28, 35, 45, 55) . The participation of TRPV4 in the maximal response elicited by 5-HT in CH PAs could be related to upregulation of TRPV4 channels similar to the CH rat model (72) . It could also be related to the enhanced PLA 2 /arachidonic acid/cytochrome-P450 epoxygenase/EETs signaling pathway. Previous studies showed that exposure of mice to hypoxia upregulates cytochrome-P450 epoxygenases and downregulates the soluble epoxide hydrolase, resulting in the increase in EET production and accumulation in the lungs (29, 52) . Stimulation of PLA 2 by 5-HT, hence, may generate a stronger stimulus for TRPV4 activation to potentiate vasoconstriction in CH PAs. The enhanced EET-TRPV4 mechanism can be important for CHPH development, as inhibition of cytochrome-P450 epoxygenases attenuates whereas deletion of the soluble epoxide hydrolase gene exaggerates CHPH (29, 52) .
It has to be emphasized, however, that TRPV4 is just one of the many pathways participating in 5-HT-induced pulmonary vasoconstriction, and other effectors such as NADPH oxidases, Ca 2ϩ -activated Cl Ϫ channels, and Rho-kinase are known to be involved in the enhanced pulmonary vasoreactivity in CHPH (3, 20, 25, 39, 58) . Nevertheless, TRPV4 may participate cooperatively with the other mechanisms to reinforce the alteration in pulmonary vascular reactivity.
5-HT (M)
We have previously shown that CH upregulates TRPV4 expression in rat PAs, and its upregulation is associated with enhanced basal vasomotor and myogenic tone. The increase in RVSP and right heart hypertrophy is delayed and suppressed, and vascular remodeling is attenuated in CH trpv4 Ϫ/Ϫ mice (72). Here, by using an open-chest approach, we further confirm that the elevation of mean PAP and pulmonary vascular resistance is greatly suppressed in CH trpv4 Ϫ/Ϫ mice without significant alteration of cardiac output. Hence, the participation of TRPV4 in CHPH is solely restricted to pulmonary vasculature and is independent of cardiac function. Recent evidence from others also shows that CH enhances TRPV4-induced Ca 2ϩ release from ryanodine-sensitive Ca 2ϩ stores in rat PASMCs (6) and activation of TRPV4 promotes PASMC migration (47) . Taking all these pieces of information together, we postulate that TRPV4 in PASMCs contributes to the development of CHPH through multifaceted influences on Ca 2ϩ influx and release, promoting basal and myogenic tone, cell migration, and vascular reactivity to collectively muster an elevation of pulmonary vascular resistance and vascular remodeling. Recent research in other areas has pinpointed the involvement of TRPV4 in many different diseases (50) and has suggested TRPV4 as an important therapeutic target (61) . In view of its roles in multiple pathological changes in CHPH, TRPV4 can be considered as a potential target for the treatment of pulmonary hypertension.
Our experiments for evaluating TRPV4 antagonists in PAs of trpv4 Ϫ/Ϫ mice raise concern for the use of high concentrations of TRPV4 antagonists. HC-067047 and RN-1747 are the two currently commercially available TRPV4-specific antagonists with IC 50 of 17 nM and 5.9 M, respectively (17, 63) . Both antagonists have been used to inhibit TRPV4 in different cell types, and HC-067047 has been shown to block TRPV4 currents and Ca 2ϩ signals in PASMCs (6, 47) . Even though these antagonists are selective for TRPV4 against other TRP channels, they have dramatic off-target effects at the commonly used concentrations on KCl and PE-induced vasoconstriction of PAs and perhaps on other smooth muscles. The side effects could be related to the inhibition of voltage-dependent Ca 2ϩ influx and/or the downstream mechanisms. This is rather problematic in the case of RN-1747, which caused ϳ20% relaxation of KCl-induced contraction in trpv4 Ϫ/Ϫ PAs at a concentration (5 M) equivalent to its IC 50 for TRPV4 inhibition. This precludes its use in experiments on vascular reactivity. In view of these findings, the off-target effects of TRPV4 antagonists should also be considered in other cells and tissues, and the results of previous studies using high concentrations of these antagonists need to be interpreted with caution.
In conclusion, we have used both pharmacological and genetic tools to evaluate the role of TRPV4 in pulmonary vascular reactivity. We found unequivocally that TRPV4 contributes to 5-HT-mediated pulmonary vasoconstriction and is responsible in part for the enhanced 5-HT-induced response in CHPH. Together with its roles in enhanced myogenic tone, PASMC migration, and pulmonary vascular remodeling, TRPV4 presents itself as an important player in the development of CHPH.
